Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus

Figures & data

Table 1 List of clinical studies on topical calcineurin inhibitors for CLE

Drug compound	CLE subtype	Protocol	Study type	Reference
Tacrolimus 0.3% combined with clobethasol 0.05%	DLE	6–8 weeks twice daily	case report	Walker et al^Citation60
Tacrolimus 0.1%	SLE, DLE	4 weeks once daily	case report	Yoshimasu et al^Citation61
Tacrolimus 0.1% or 0.03%	SLE, SCLE	5–8 weeks once or twice daily	case report	Böhm et al^Citation62
Tacrolimus 0.1%	LET	4 weeks twice daily	case report	Bacman et al^Citation63
Tacrolimus 0.1%	SLE	4 weeks twice daily	case report	Kanekura et al^Citation64
Tacrolimus 0.1%	DLE	8 weeks twice daily	case report	de la Rosa Carillo and Christensen^Citation65
Tacrolimus 0.1%	SCLE	8 weeks twice daily	case report	Drüke et al^Citation66
Tacrolimus 0.1%	SLE, SCLE, DLE	>6 weeks twice daily	open label study	Lampropoulos et al^Citation67
Tacrolimus 0.1%	SCLE	3 weeks twice daily	case report	Meller et al^Citation68
Tacrolimus 0.1%	DLE	12 weeks twice daily	open label study	Heffernan et al^Citation69
Tacrolimus 0.1%	DLE	4–8 weeks twice daily	case report	Sugano et al^Citation70
Tacrolimus 0.1%	SLE, DLE	3 weeks twice daily 4-week follow-up	case report	von Pelchrzim et al^Citation71
Tacrolimus 0.1% vs 0.05% clobetasol proprionate	SLE, SCLE, DLE	4 weeks twice daily	randomized double blind bilateral comparison	Tzung et al^Citation72
Tacrolimus 0.03%	SCLE	6 weeks	case report	Cooper et al^Citation73
Tacrolimus 0.3%/0.005 clobetasol vs.tacrolimus 0.1%	DLE, SCLE, SLE	twice daily	retrospective study	Madan et al.^Citation74
Tacrolimus 0.03%	linear DLE	one year	case report	Kawachi et al.^Citation75
Tacrolimus 0.1%	DLE	8 weeks twice daily	case report	Han et al.^Citation76
Pimecrolimus 1% cream	DLE	8 weeks twice daily	case report	Han et al.^Citation76
Pimecrolimus 1% cream		not given	case report	Zabawski^Citation77
Pimecrolimus 1% cream	SLE, SCLE DLE, LET	3 weeks twice daily 8-week follow-up	open label study	Kreuter et al^Citation78
Pimecrolimus 1% cream	DLE	8 weeks twice daily	open label study	Tlacuilo-Parra et al^Citation79
Pimecrolimus 1% cream vs placebo	SCLE, DLE	4 weeks twice daily 4-week follow-up	randomized double blind, placebo controlled, bilateral comparison	Sticherling et al^Citation80
Pimecrolimus 1% cream vs 0.1% betamethasone	DLE	8 weeks twice daily	randomized double blind	Barikbin et al^Citation81

WalkerSLKirbyBChalmersRJThe effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosusBr J Dermatol200214740540612174136

 PubMed Web of Science ®Google Scholar

YoshimasuTOhtaniTSakamotoTTopical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositisEur J Dermatol200212505211809595

 PubMed Web of Science ®Google Scholar

BöhmMGaubitzMLugerTATopical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three casesDermatology200320738138514657631

 PubMed Web of Science ®Google Scholar

BacmanDTanbajewaAMegahedMTopical treatment with tacrolimus in lupus erythematosus tumidusHautarzt20035497797914513247

 PubMed Web of Science ®Google Scholar

KanekuraTYoshiiNTerasakiKEfficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosusBr J Dermatol200314835335612588393

 PubMed Web of Science ®Google Scholar

De la Rosa CarrilloDChristensenOBTreatment of chronic discoid lupus erythematosus with topical tacrolimusActa Derm Venereol200484323323415202845

 PubMed Web of Science ®Google Scholar

DrükeAGambichlerTAltmeyerP0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosusJ Dermatolog Treat200415636414754655

 PubMedGoogle Scholar

LampropoulosCESangleSHarrisonPTopical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternativeRheumatology2004431383138515266063

 PubMed Web of Science ®Google Scholar

MellerSBruch-GerharzDRuzickaTTopische Behandlung des subakut-kutanen Lupus erythematodes mit TacrolimusHautarzt20055636836915750673

 PubMed Web of Science ®Google Scholar

HeffernanMPNelsonMMSmithDI0.1% tacrolimus ointment in the treatment of discoid lupus erythematosusArch Dermatol20051411170117116172325

 PubMedGoogle Scholar

SuganoMShintaniYKobayashiKSuccessful treatment with topical tacrolimus in four cases of discoid lupus erythematosusJ Dermatol20063388789117169097

 PubMed Web of Science ®Google Scholar

Von PelchrzimRSchmookTFriedrichMEfficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosusInt J Dermatol200645848516426386

 PubMed Web of Science ®Google Scholar

TzungTYLiuYSChangHWTacrolimus vs clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison studyBr J Dermatol200715619119217199600

 PubMed Web of Science ®Google Scholar

CooperRMButlerDFGhaliFPeriorbital cutaneous neonatal lupusSkinmed20076314514617483660

 PubMedGoogle Scholar

MadanVAugustPJChalmersRJEfficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort studyClin Exp Dermatol201035273019549244

 PubMed Web of Science ®Google Scholar

KawachiYTaguchiSFujisawaYFurutaJNakamuraYIshiiYOtsukaFLinear Childhood Discoid Lupus Erythematosus Following the Lines of Blaschko: Successfully Treated with Topical TacrolimusPediatr Dermatol201091 [Epub ahead of print]

 Google Scholar

HanYWKimHOParkSHParkYMFour cases of facial discoid lupus erythematosus successfully treated with topical pimecrolimus or tacrolimusAnn Dermatol20102230731120711267

 PubMed Web of Science ®Google Scholar

ZabawskiETreatment of cutaneous lupus with ElidelDermatol Online J2002822512546779

 PubMedGoogle Scholar

KreuterAGambichlerTBreuckmannFPimecrolimus 1% cream for cutaneous lupus erythematosusJ Am Acad Dermatol20045140741015337984

 PubMed Web of Science ®Google Scholar

Tlacuilo-ParraAGuevara-GutiérrezEGutiérrez-MurilloFPimecrolimus 1% cream for the treatment of discoid lupus erythematosusRheumatology2005441564156816159951

 PubMed Web of Science ®Google Scholar

SticherlingMGelbrichGRogalskiCTopical pimecrolimus for cutaneous lupus erythematosus – results of a double-blind, placebo controlled studyJ Deutsch Dermatol Ges20075S188S1889

 Google Scholar

BarikbinBGivradSYousefiMPimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot studyClin Exp Dermatol20093477678019456797

 PubMed Web of Science ®Google Scholar